

Summary Report for Policy-Makers

# Niraparib in Ovarian Cancer

## **Report Authors**


Qi Guan, Suriya Aktar, Reka Pataky, Mariet Mathew Stephen, Maud Marques, Karen Gambaro, Katharina Forster, Samara Strub, Winson Y Cheung, Stuart Peacock, Christie Farrer, Scott Gavura, Mina Tadrous, Robert Grant, Kelvin KW Chan

## **Knowledge Translation Support**

Emily Farrell

# Executive Summary

Clinical trials have shown that niraparib can cause hematological toxicity. However, event rates in clinical trials may differ from those in the real world. This study aims to determine if the safety profile of niraparib in real-world patient populations differs from the clinical trial findings, using data from 4 provinces: Ontario, British Columbia, Alberta, and Quebec. The study found that the occurrence of adverse events was lower in the real-world setting than what is reported in clinical trials. The findings suggest that the real-world administration of niraparib is at lower doses than those recommended in the product monograph. Clinicians taking a cautious dosing approach and proactively monitoring for and managing adverse events could have contributed to the lower proportion of hematological toxicities observed in the real world. More research is needed to further guide clinical decisions.



# Background

Niraparib (a poly-(adenosine diphosphate [ADP]-ribose) polymerase [PARP] inhibitor) is used as a maintenance therapy for patients with new or recurrent epithelial ovarian cancer, whose disease has a complete or partial response to platinum-based chemotherapy. Clinical trials have shown that PARP inhibitors can cause hematological toxicity (an adverse effect on blood or blood-forming tissues), with the most common being thrombocytopenia (low blood platelet count), anemia (low red blood cell count), neutropenia (low white blood cell count), fatigue, and high blood pressure. Most patients in these trials required a dose interruption or reduction to manage these adverse events.

## Policy Issue

Niraparib is reimbursed as a maintenance treatment for newly diagnosed and recurrent ovarian, fallopian tube, or primary peritoneal cancer. Given the toxicity rates seen in clinical trials, policy-makers want to further understand the risk profile of niraparib in managing ovarian cancer in real-world scenarios. This information can help inform patient monitoring and toxicity management measures.

## Objective

The objective of the observational study was to describe the clinical and demographic characteristics of patients receiving niraparib treatment in real-world settings and the proportion of this patient population that experienced adverse events.

## Policy Question

How does the safety and tolerability of niraparib in the real world compare with observations from the seminal clinical trials?

# Results

## Population

The study included **514 patients** undergoing maintenance treatment for newly diagnosed or recurrent ovarian cancer, with 483 using publicly funded niraparib (338 in Ontario, 45 in Alberta, and 100 in British Columbia) and 31 identified in the Personalize My Treatment Registry (31 in Quebec).

The overall characteristics of the included patient population were:

- Two-thirds of the patients were aged 65 years or older.
- More than half of the patients were diagnosed with ovarian cancer between 2020 and 2022.
- The ovaries were the most common primary tumour location.
- Most patients started niraparib treatment in 2022 after completing platinum-based chemotherapy.
- The most common initial daily dose of niraparib was 200 mg per day, followed by 100 mg per day, and 300 mg per day (the standard recommended dose is 300 mg per day).

## Hematological Adverse Events

Adverse events are classified into 5 severity grades (1 = mild, 2 = moderate, 3 = severe, 4 = life threatening, and 5 = death).

The following proportions of patients experienced hematological adverse events of **any grade** across all provinces:

- Anemia: 76.8%
- Thrombocytopenia: 41.5%
- Neutropenia: 39.3%

Across all provinces, **grade 3 or 4** hematological adverse events occurred in approximately 10% to 12% of the overall patient population:

- Anemia: 12.2% (Seminal clinical trials: PRIMA trial = 31.0%; NOVA trial = 25.3%; NORA trial = 14.7%)
- Thrombocytopenia: 11.7% (Seminal clinical trials: PRIMA trial = 28.7%; NOVA trial = 33.8%; NORA trial = 11.3%)
- Neutropenia: 10.8% (Seminal clinical trials: PRIMA trial = 12.8%; NOVA trial = 19.6%; NORA trial = 20.3%)

Approximately 20% of the patient population were newly diagnosed with high blood pressure and very few (< 10 patients) experienced febrile neutropenia.

**Key takeaway:** The occurrence of severe adverse events was lower in the real-world setting in all participating Canadian jurisdictions than what is reported in the clinical trials.

## Limitations

There are 3 key limitations to this study. First, the results may have limited generalizability to the broader population in Canada; however, this may be minor given that the trends are relatively consistent across the provinces included in this study. Second, the observation window for the study was limited for some patients because niraparib was only recently publicly funded in Canada, which may undercount the number of hematological adverse events. Third, patient weight data are lacking, making it difficult to determine if those who started with 200 mg of niraparib received a personalized dose based on weight. Additionally, it is unclear if some patients who started on lower doses were subsequently titrated upward during their treatment.

## Implications for Policy-Making

There is a lower proportion of hematological toxicities observed in the real world compared to the clinical trial findings. The reason for this difference is not clear; however, researchers believe that it might be due to:

- clinicians taking a cautious dosing approach by starting their patients at a lower dose than recommended, and
- proactive monitoring via regular bloodwork and managing adverse events as early as possible.

The current analysis shows that niraparib is used carefully and at low initial doses in 4 provinces across Canada. Patients receiving niraparib maintenance treatment are not free of adverse events, but proactive management by clinicians may be preventing them from progressing to grade 3 or 4.

More research is needed to further guide clinical and/or policy decisions on the use of niraparib maintenance treatment.

For more information on CoLab and its work visit the [CoLab website](#).



This work was supported by CADTH and its Post-Market Drug Evaluation Program, through funding provided by Health Canada.

Disclaimer: The information in this document is made available for informational and educational purposes only and should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect to the care of a particular patient or other professional judgment in any decision-making process. You assume full responsibility for the use of the information and rely on it at your own risk.

The Canadian Agency for Drugs and Technologies in Health (CADTH) has taken care to ensure that the information in this document was accurate, complete, and up to date when it was published, but CADTH does not make any guarantee to that effect. Your use of this information is subject to this disclaimer and the Terms of Use at [cadth.ca](http://cadth.ca). CADTH does not endorse any information, drugs, therapies, treatments, products, processes, or services. The views and opinions of third parties published in this document do not necessarily reflect those of CADTH.

About CADTH: CADTH is a not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs and medical devices in our health care system.

About CoLab: CoLab is a pan-Canadian network of experts in applied research, scientific methods, and data analysis. CoLab members work with CADTH's Post-Market Drug Evaluation Program to produce credible and timely evidence on post-market drug safety and effectiveness.

This document is the property of the Canadian Cancer Real-World Evaluation (CCRE) Platform and Exactis Innovation. CADTH has a nonexclusive, limited, royalty-free, worldwide, nontransferable, fully paid-up, and irrevocable license to use the report in support of its objects and mission and reasonable operational requirements.